F. Hoffmann-La Roche is a Switzerland-based healthcare company spanning pharmaceuticals and diagnostics. Founded in Basel in 1896, Roche has grown into the world’s largest biotechnology company and a global leader in in-vitro diagnostics.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598396 |
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis |
RECRUITING | PHASE2 |
| NCT07589686 |
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07588100 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07555938 |
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07553442 |
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran |
RECRUITING | PHASE2 |
| NCT07541170 |
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07531719 |
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA) |
NOT_YET_RECRUITING | |
| NCT07527741 |
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization |
RECRUITING | |
| NCT07503340 |
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07499050 |
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight |
RECRUITING | PHASE1 |
